Skip to content

Chemed CHE Granted (in dollars per share)

Granted (in dollars per share) at other companies

CHE
ChemedCHE
514.4-8.8%
Belden logo
BeldenBDC
$120.25+33.6%
General Motors logo
General MotorsGM
$50.88+21.8%
Accenture logo
AccentureACN
$346.49+1.4%
Repligen logo
RepligenRGEN
$125.03
Flagstar Bank
 logo
Flagstar Bank FLG
$0.00

Other financials

Income statement

See full
Revenue$657.5M+1.6%
Gross profit$215.8M-0.3%
Operating income$84.6M-10.7%
Net income$66.3M-7.6%
EPS (diluted)$4.84-0.4%

Balance sheet

See full
Cash & equivalents$16.9M-90.3%
Total debt$236.9M+63.3%
Total equity$848.0M-28.2%
Total assets$1.5B-11.0%

Cash flow

See full
Operating cash flow$88.2M+169%
CapEx$17.1M+28.9%
Free cash flow$71.1M+265%

Valuation

See full
Market cap$5.79B-42.3%
Enterprise value$6.01B-39.6%
P/E22.3×-10.2×
P/S2.3×-1.8×

Profitability

See full
Gross margin32.4%-2.4pp
Operating margin12.9%-2.7pp
Net margin10.2%-2.2pp
FCF margin14.8%+2.2pp

Returns & leverage

See full
Return on equity25.6%-0.5pp
Debt / equity0.3×+0.2×
Current ratio0.9×-0.9×

Where this comes from

Reported directly by Chemed in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue.

The official record: Chemed’s 10-K, filed February 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Chemed's granted (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Chemed's granted (in dollars per share)?
Chemed (CHE) reported granted (in dollars per share) of 514.4 in Q4 2025.
How has Chemed's granted (in dollars per share) changed year-over-year?
Chemed's granted (in dollars per share) decreased by 8.8% year-over-year, from 564.3 to 514.4.
What does granted (in dollars per share) mean?
The weighted average grant-date fair value per share for equity awards granted during the period. This figure provides insight into the cost the company incurs to issue equity-based compensation and the perceived value of these awards at the time of grant.